Drug companies wrestle for control of multibillion-dollar pain drug market

After Purdue and Endo Pharmaceuticals ($ENDP) developed new, tamper-resistant versions of their often-abused narcotic painkillers, they're now trying to stop generic drugmakers from rolling out copycats of the older drugs now coming off of patent protection. The drug companies say it's a safety issue. The generic competition, though, says it's about economics. Patients shouldn't be denied cheaper meds, they say, which can be very safe if used properly. With a big chunk of a $9 billion drug market up for grabs, this is one argument that is likely to continue for some time. Story (sub. req.)

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.